Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: A case study of anticancer drug, crizotinib

AAPS Journal

Volumn 15, Issue 2, 2013, Pages 354-366

  Yamazaki, Shinji ^a  

^a PFIZER INC   (United States)

Author keywords

cancer; crizotinib; PKPD; translational pharmacology

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER INHIBITION; CANCER RESEARCH; CLINICAL PHARMACOLOGY; CONCENTRATION (PARAMETERS); DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; HUMAN; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MATHEMATICAL ANALYSIS; MAXIMUM PLASMA CONCENTRATION; MEDIAN EFFECTIVE CONCENTRATION; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; STEADY STATE; TRANSLATIONAL RESEARCH; TUMOR VOLUME; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DISCOVERY; DRUG DOSAGE CALCULATIONS; HUMANS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLATIONAL MEDICAL RESEARCH; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877018103     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9436-4     Document Type: Review

References (55)

1. Chien JY, Friedrich S, Heathman MA, de Alwis DP, Sinha V. Pharmacokinetics/Pharmacodynamics and the stages of drug development: Role of modeling and simulation. AAPS J. 2005;7:E544-59.
2. Cohen A. Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies. Clin Pharmacokinet. 2008;47:373-81.
3. Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol. 2000;40:1399-418.
4. Lesko LJ, Rowland M, Peck CC, Blaschke TF. Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res. 2000;17:1335-44.
5. Senderowicz AM. Information needed to conduct first-in-human oncology trials in the United States: A view from a former FDA medical reviewer. Clin Cancer Res. 2010;16:1719-25.
6. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today. 2012.
7. Anger GJ, Piquette-Miller M. Translational pharmacology: harnessing increased specialization of research within the basic biological sciences. Clin Pharmacol Ther. 2008;83:797-801.
8. Lotsch J, Geisslinger G. Bedside-to-bench pharmacology: A complementary concept to translational pharmacology. Clin Pharmacol Ther. 2010;87:647-9.
9. Mager DE, Jusko WJ. Development of translational pharmacokinetic- pharmacodynamic models. Clin Pharmacol Ther. 2008;83:909-12.
10. Lindner MD. Clinical attrition due to biased preclinical assessments of potential efficacy. Pharmacol Ther. 2007;115:148-75.
11. Schuster D, Laggner C, Langer T. Why drugs fail-a study on side effects in new chemical entities. Curr Pharm Des. 2005;11:3545-59.
12. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: Better than commonly perceived-but they can be improved. Cancer Biol Ther. 2003;2:S134-9.
13. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer. 2004;40:837-44.
14. Kelland LR. Of mice and men: Values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer. 2004;40:827-36.
15. Burchill SA. What do, can and should we learn from models to evaluate potential anticancer agents? Future Oncol. 2006;2:201-11.
16. Hollingshead MG. Antitumor efficacy testing in rodents. J Natl Cancer Inst. 2008;100:1500-10.
17. Liu L, Di Paolo J, Barbosa J, Rong H, Reif K, Wong H. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: Relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther. 2011;338:154-63.
18. Salphati L, Wong H, Belvin M, Bradford D, Edgar KA, Prior WW, et al. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos. 2010;38:1436-42.
19. Wong H, Belvin M, Herter S, Hoeflich KP, Murray LJ, Wong L, et al. Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3- (pyridine-4-yl)-1H-pyraz ol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: Understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J Pharmacol Exp Ther. 2009;329:360-7.
20. Yamazaki S, Nguyen L, Vekich S, Shen Z, Yin MJ, Mehta PP, et al. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model. J Pharmacol Exp Ther. 2011;338:964-73.
21. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, et al. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos. 2008;36:1267-74.
22. Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, et al. Pharmacokinetic-pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and anti-tumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther. 2012.
23. Cui JJ, Tran-Dube M, Shen H, Nambu M, Kung PP, Pairish M, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011;54:6342-63.
24. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693-703.
25. Ou SH. Crizotinib: A novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther. 2011;5:471-85.
26. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190-203.
27. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-6.
28. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol. 2012.
29. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw. 2011;9:1335-41.
30. Tan W, Wilner KD, Bang Y, Kwak EL, Maki RG, Camidge DR. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. J Clin Oncol. 2010;28:15s.
31. Sheiner LB. The population approach to pharmacokinetic data analysis: Rationale and standard data analysis methods. Drug Metab Rev. 1984;15:153-71.
32. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21:457-78.
33. Mager DE, Wyska E, Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003;31:510-8.
34. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin Pharmacol Ther. 1979;25:358-71.
35. Bissery MC, Vrignaud P, Lavelle F, Chabot GG. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs. 1996;7:437-60.
36. Gompertz B. On the Nature of the Function Expressive of the Law of Human Mortality, and on a New Mode of Determining the Value of Life Contingencies. Phil Trans R Soc London. 1825;115:513-85.
37. Hart D, Shochat E, Agur Z. The growth law of primary breast cancer as inferred from mammography screening trials data. Br J Cancer. 1998;78:382-7.
38. Lobo ED, Balthasar JP. Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro. AAPS PharmSci. 2002;4:E42.
39. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 2004;64:1094-101.
40. Sun YN, Jusko WJ. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci. 1998;87:732-7.
41. Butterfield LH, Potter DM, Kirkwood JM. Multiplex serum biomarker assessments: Technical and biostatistical issues. J Transl Med. 2011;9:173.
42. Godschalk RW, Van Schooten FJ, Bartsch H. A critical evaluation of DNA adducts as biological markers for human exposure to polycyclic aromatic compounds. J Biochem Mol Biol. 2003;36:1-11.
43. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2008;14:7917-23.
44. FDA. Xalkori Clinical Pharmacology and Biopharmaceutical Review(s) (http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/ 202570Orig1s000ClinPharmR.pdf). 2011.
45. Zou HY, Li Q, Lee J, Engstrom L, Lu MW, Young A, et al. Antitumor efficacy of crizotinib (PF-02341066), a potent and selective ALK and c-Met RTK inhibitor. In: EML4-ALK driven NSCLC tumors in vitro and in vivo. At the 102nd AACR Annual Meeting; April 2-6, 2011, Orlando, Florida Abstract LB-390. American Society for Cancer Research, Philadelphia, PA; 2011.
46. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007;67:4408-17.
47. Yamazaki S, Skaptason J, Romero D, Vekich S, Jones HM, Tan W, et al. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. Drug Metab Dispos. 2011;39:383-93.
48. Sugawara M, Okamoto K, Kadowaki T, Kusano K, Fukamizu A, Yoshimura T. Expressions of cytochrome P450, UDP-glucuronosyltranferase, and transporter genes in monolayer carcinoma cells change in subcutaneous tumors grown as xenografts in immunodeficient nude mice. Drug Metab Dispos. 2010;38:526-33.
49. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6:3314-22.
50. Jusko WJ, Ko HC, Ebling WF. Convergence of direct and indirect pharmacodynamic response models. J Pharmacokinet Biopharm. 1995;23:5-8. discussion 9-10.
51. Kreeger PK, Lauffenburger DA. Cancer systems biology: A network modeling perspective. Carcinogenesis. 2010;31:2-8.
52. Teicher BA. Tumor models for efficacy determination. Mol Cancer Ther. 2006;5:2435-43.
53. Takimoto CH. Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development. Eur J Cancer. 2009;45 Suppl 1:436-8.
54. Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, et al. Antitumor activity of targeted and cytotoxic agents in xenograft models correlates with clinical response: A pharmacokinetic-pharmacodynamic analysis. Mol Cancer Ther. 2011;10:Abstract A11.
55. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6:942-6.